Cosette Pharmaceuticals Announces the Approval and Launch of Metronida...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 19, 2024

US Consumers’ 2024 Sustainability Score Declines and Lags the Global Average, According to New Report • Kontoor Brands Declares Quarterly Dividend • New Evergreen Impact Housing Fund, GMD Development project brings 145 affordable units to Renton • New Jersey Natural Gas to Reduce Fleet Emissions with Neste MY Renewable Diesel • ATIXA Announces a Central Resource Hub for 2024 Title IX Regulations • Sensi.AI Appoints Renowned Home Care Advocate, Bob Roth, to its Advisory Board Combining Data-Driven Insights with Decades of Ho • Avangrid Thanks Southern Connecticut Gas Employee for 51 Years of Service • Two 1440 Media Marketing Leaders Honored as Top Women In Media & Ad Tech • Solar Sector Sees $8.1 Billion in Corporate Funding in Q1 2024, Reports Mercom Capital Group • Surfrider Foundation Launches Innovative Climate Action Program: Empowering Communities to Restore Coastlines and Combat Climate • Ziegler Advises Retirement Housing Foundation on The Sale Of 15-Community Portfolio • Energy Vault Schedules Inaugural Investor & Analyst Day for May 9, 2024; Schedules Release Date for First Quarter 2024 Finan • PURETALK CUSTOMERS SURPASS $100,000 IN DONATIONS TO AMERICA'S WARRIOR PARTNERSHIP • Gotodoctor acquires Industry Veteran Kevin Dougherty to its advisor board • Consolidated Communications Releases 2023 Environmental, Social and Governance Report • PRNEWS names Ripley PR founder and CEO Heather Ripley as 2024 Top Women honoree • Bernhard and Hackensack Meridian Health Forge a Transformative 30-Year Energy Partnership, HMH Hospitals to be Largest Renewable • Dr. Ron: The Pioneer of Next Level Deep Plane Face and Neck Lift • MCR and BLT Complete $632 Million Refinancing of 53-Hotel Portfolio • THE TECH INTERACTIVE IGNITES NATIONAL AI LITERACY DAY WITH INAUGURAL SUMMIT IN SAN JOSE

Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%

BRIDGEWATER, N.J. , February 09 /Businesswire/ - Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for Metronidazole Gel USP, 1%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230209005033/en/

Metronidazole Gel (Photo: Business Wire)

This launch will enable Cosette to continue to build upon its unparalleled quality track record and leverage its United States based manufacturing site in Lincolnton, NC.

Apurva Saraf, President and CEO of Cosette Pharma, stated, "The continued approval and launches of our internal R&D programs highlights our commitment to world class R&D and operational excellence. We are Innovating Every Day and are committed to growing our pipeline and portfolio of products through R&D and global business development partnerships”

According to IQVIA™, U.S. market annual sales for the 12 months ended December 2022 for Metronidazole Gel USP, 1% is estimated to be approximately $17 million.

See the Full Prescribing Information and Instructions for Use for Metronidazole Gel, USP 1% at www.dailymed.com.

About Cosette Pharmaceuticals, Inc.:

Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette has a fast-growing portfolio of branded pharmaceuticals, consisting of products in cardiology, women’s health and pediatrics. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com